Centre for Trials Research, Cardiff University, Cardiff, UK.
The Welsh Centre for Primary and Emergency Care Research (PRIME), Division of Population Medicine, Cardiff University, Cardiff, UK.
Health Technol Assess. 2023 Jan;27(1):1-224. doi: 10.3310/NKIX8285.
Women with overweight (a body mass index of ≥ 25 kg/m) or obesity (a body mass index of ≥ 30 kg/m) are at greater risk of experiencing complications during pregnancy and labour than women with a healthy weight. Women who remove their long-acting reversible contraception (i.e. coils or implants) are one of the few groups of people who contact services as part of their preparation for conception, creating an opportunity to offer a weight loss intervention.
The objectives were to understand if routine NHS data captured the pathway from long-acting reversible contraception removal to pregnancy and included body mass index; to identify the suitable components of a preconception weight loss intervention; and to engage with key stakeholders to determine the acceptability and feasibility of asking women with overweight/obesity to delay the removal of their long-acting reversible contraception in order to take part in a preconception weight loss intervention.
This was a preparatory mixed-methods study, assessing the acceptability and feasibility of a potential intervention, using routine NHS data and purposefully collected qualitative data.
The NHS routine data included all women with a long-acting reversible contraception code. There were three groups of participants in the surveys and interviews: health-care practitioners who remove long-acting reversible contraception; weight management consultants; and women of reproductive age with experience of overweight/obesity and of using long-acting reversible contraception.
UK-based health-care practitioners recruited at professional meetings; and weight management consultants and contraceptive users recruited via social media.
Anonymised routine data from UK sexual health clinics and the Clinical Practice Research Datalink, including the Pregnancy Register; and online surveys and qualitative interviews with stakeholders.
The records of 2,632,871 women aged 16-48 years showed that 318,040 had at least one long-acting reversible contraception event, with 62% of records including a body mass index. Given the identified limitations of the routine NHS data sets, it would not be feasible to reliably identify women with overweight/obesity who request a long-acting reversible contraception removal with an intention to become pregnant. Online surveys were completed by 100 health-care practitioners, four weight management consultants and 243 contraceptive users. Ten health-care practitioners and 20 long-acting reversible contraception users completed qualitative interviews. A realist-informed approach generated a hypothesised programme theory. The combination of weight discussions and the delay of long-acting reversible contraception removal was unacceptable as an intervention to contraceptive users for ethical and practical reasons. However, a preconception health intervention incorporating weight loss could be acceptable, and one potential programme is outlined.
There was very limited engagement with weight management consultants, and the sample of participating stakeholders may not be representative.
An intervention that asks women to delay long-acting reversible contraception removal to participate in a preconception weight loss intervention would be neither feasible nor acceptable. A preconception health programme, including weight management, would be welcomed but requires risk communication training of health-care practitioners.
Work to improve routine data sets, increase awareness of the importance of preconception health and overcome health-care practitioner barriers to discussing weight as part of preconception care is a priority.
This trial is registered as ISRCTN14733020.
This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in ; Vol. 27, No. 1.
与健康体重的女性相比,超重(体重指数≥25kg/m)或肥胖(体重指数≥30kg/m)的女性在怀孕期间和分娩时更有可能出现并发症。取出长效可逆避孕措施(即宫内节育器或皮下埋植剂)的女性是少数在准备怀孕时联系服务的人群之一,这为提供减肥干预措施创造了机会。
了解常规国民保健服务(NHS)数据是否能捕捉到长效可逆避孕措施取出到怀孕的途径,以及是否包括体重指数;确定适合孕前减肥干预的组成部分;并与主要利益相关者接触,以确定让超重/肥胖的女性延迟取出长效可逆避孕措施以参加孕前减肥干预的可接受性和可行性。
这是一项预备性混合方法研究,使用常规 NHS 数据和有针对性收集的定性数据来评估潜在干预措施的可接受性和可行性。
NHS 常规数据包括所有使用长效可逆避孕措施的代码的女性。在调查和访谈中有三组参与者:取出长效可逆避孕措施的医疗保健从业者;体重管理顾问;以及有超重/肥胖经历且使用长效可逆避孕措施的育龄妇女。
英国的医疗保健从业者在专业会议上招募;体重管理顾问和避孕使用者通过社交媒体招募。
包括妊娠登记在内的英国性健康诊所和临床实践研究数据链接的匿名常规数据;以及利益相关者的在线调查和定性访谈。
记录了 2632871 名 16-48 岁的女性,其中 318040 人至少有一次长效可逆避孕事件,其中 62%的记录包括体重指数。鉴于 NHS 常规数据集存在的明显局限性,无法可靠地识别出要求取出长效可逆避孕措施且打算怀孕的超重/肥胖女性。100 名医疗保健从业者、4 名体重管理顾问和 243 名避孕使用者完成了在线调查。10 名医疗保健从业者和 20 名长效可逆避孕使用者完成了定性访谈。通过现实主义方法产生了一个假设的方案理论。由于伦理和实际原因,将体重讨论和长效可逆避孕措施取出延迟相结合的干预措施对避孕使用者来说是不可接受的。然而,包含减肥的孕前健康干预措施可能是可以接受的,并且概述了一个潜在的方案。
与体重管理顾问的接触非常有限,参与的利益相关者样本可能不具有代表性。
要求女性延迟长效可逆避孕措施取出以参加孕前减肥干预的干预措施既不可行也不可接受。包括体重管理的孕前健康方案将受到欢迎,但需要对医疗保健从业者进行孕前保健中讨论体重的风险沟通培训。
优先工作是改进常规数据集,提高对孕前健康重要性的认识,并克服医疗保健从业者在讨论体重作为孕前护理一部分方面的障碍。
本试验在英国临床试验注册库(ISRCTN)注册,注册号为 ISRCTN8471456。
本项目由英国国家卫生与保健优化研究所(NIHR)健康技术评估计划资助,研究结果将全文发表于《Health Technology Assessment》杂志 2023 年第 27 卷第 1 期。